“I fought RA pain with my passion,” said Lady Gaga in the Spring 2017 issue of Arthritis magazine. Rheumatoid arthritis (RA) is an autoimmune disease with hallmark symptoms of inflammation and resulting pain. It is a disease process (like cancer or diabetes) where the body's immune system mistakenly attacks its own healthy joints. It is a relatively common disease-approximately 300,000 or 1 in 100 Canadians get it-and is often devastating to a person's body if not treated properly. The disease process causes swelling and pain in and around joints and can affect the body's organs, including the eyes, lungs, and heart. Rheumatoid arthritis most commonly affects the hands and feet. Other joints often affected include the elbows, shoulders, neck, jaw, ankles, knees, and hips. When moderate to severe, the disease reduces a person's life span by as much as a dozen years. To learn more about the disease, please click here.
In 2013, Lady Gaga had to cancel part of the Born This Way Ball world tour to get surgery after suffering a massive joint tear and hip breakage. At the time, she thought the pain was the result of a labral tear and an inflammatory condition called synovitis. She told Women's Wear Daily: "My injury was actually a lot worse than just a labral tear. I had broken my hip. Nobody knew, and I haven't even told the fans yet." Continue reading
As part of an international network of RA patient organizations, Arthritis Consumer Experts invites you to participate in a global survey of RA patients to examine the diagnosis, treatment and care they receive for their RA. The goal of this survey is to understand, from the patient experience and perspective, how current “models of care” for rheumatoid arthritis compare between countries.
Your experience and perspective matter
As a person living with RA, sharing your experiences about the care you receive is vitally important. With your help, we can meet the study goals and develop education and information programs to improve patients’ understanding about RA models of care to enable the best treatment outcomes possible in Canada.
How you can participate
If you agree to participate, you will be asked to answer a survey questionnaire, which should take approximately 10 minutes to complete. All the information gathered during the survey will be combined to protect your privacy and anonymity.
To be eligible to participate in this survey, you must:
- Be 18 years of age or older
- Receive health care in Canada
- Have access to the internet
Thank you for considering our request to participate in this survey. Your participation will help you and other people living with RA in your country know more about the health care they should be receiving.
Please click here to complete the survey.
RA Matters is an international project aiming to explore what matters most to people living with RA. Using online crowdsourcing to invite participants, RA Matters asks questions about relationships, activities, work and aspirations, in order to reveal the most important aspects of day-to-day life. RA Matters aims to elevate a global conversation that sheds light on what those with RA really want and – ultimately – help them live the best life possible.
British archer Leigh Walmsley competed at the London 2012 Paralympic game despite living with rheumatoid arthritis (RA). Her target is clear: continue to manage her RA while participating in competitive archery locally and nationally.
Walmsley experienced symptoms of RA in her 20s. She recalled feeling progressively worsening stiffness and soreness over weeks and months, especially in the morning and evening. She did not receive a diagnosis until she was 30. Even now, 24 years later, she continues to experience fatigue from RA and admits that her RA is not as controlled as she'd like it to be. Continue reading
Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.
Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).
Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading
According to a recent research study, rheumatoid arthritis (RA) patients are at an increased risk for chronic kidney disease (CKD). Along with CKD, researchers also observe increased inflammation within the first year of diagnosis, corticosteroid usage, hypertension, and obesity.
In the study, researchers monitored 813 Mayo Clinic patients with RA and 813 patients without RA for 20 years. They found that RA patients had a one in four chance of developing CKD, while the general public had a one in five chance. "That might not seem like a lot, but in fact that's quite a big difference, and it has important implications for the course of rheumatoid arthritis and for the management of the disease," said Dr. Eric Matteson, senior author of the study. Continue reading